CIHR-ICRH/CCS Mid-Career Lecturer Award in Cardiovascular Sciences
The CIHR-ICRH and the Canadian Cardiovascular Society (CCS) have partnered on the Mid-Career Lecturer Award in Cardiovascular Sciences to recognize an individual's outstanding contribution to the advancement of cardiovascular sciences both in Canada and internationally at the mid-point of their career. The award will be presented to the selected candidate at the Canadian Cardiovascular Congress, where the recipient will deliver a lecture as part of the scientific program. The CCC is the largest gathering of cardiovascular and allied health professionals in Canada.
Dr. Jason Andrade – Recipient of the 2023 CIHR-ICRH/CCS Mid-Career Lecturer Award in Cardiovascular Sciences
Dr. Andrade is a Cardiac Electrophysiologist at Vancouver General Hospital in Canada, with joint appointment at the Montreal Heart Institute. Dr. Andrade is the Director of Electrophysiology at Vancouver General Hospital (VGH). He is an Associate Professor of Medicine at the University of British Columbia (UBC), and an Assistant Professor at the Université de Montréal.
Dr. Andrade is co-chair of the Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines and the CCS Device Therapy Guidelines, chair of the Canadian Heart Rhythm Society (CHRS) Device Committee, and medical chair for Heart Rhythm Disease for the Cardiovascular Disease Network in the province of British Columbia. He is the author of over 250 scientific publications and is on the editorial board of several journals.
Dr. Andrade's research interest is focused on the Atrial fibrillation, where he has led several multicenter randomized clinical trials. He was the principal investigator of the CIRCA-DOSE multicenter randomized clinical trial, transformative in its use of invasive cardiac monitoring, being described as providing "invaluable" information to "the patient, the electrophysiologist, and the medical community" (Calkins, Circulation 2019). He was also the principal investigator of the EARLY-AF multicenter randomized clinical trial, which was described as a "game-changer for heart rhythm treatment" and has been highlighted as a top study of 2020 (Medscape 2020, European Heart Journal 2021). Principal investigator of the PROGRESSIVE-AF multicenter randomized clinical trial, which was recognized as one of the top clinical trials in 2022 by the American College of Cardiology and Journal Watch.
- Date modified: